• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2025.20071

Survival rate of genetically engineered biological therapy for psoriasis and psoriatic arthritis

[Dermatology]
Elena Vladimirovna Svechnikova; Svetlana Evgenievna Zhufina; Natalia Alexandrovna Merzlikina; Vasily Stanislavovich Babanin; Elena Vasilevna Rzhevskaya;

Psoriasis and psoriatic arthritis require a long-term therapeutic control, and the study of biologic therapy survival helps optimize treatment and improve patients’ quality of life. A single-center cohort study conducted between 2017 and 2025 included 51 patients (59 % men, mean age 53.3±12.6 years, mean disease duration 14 [10; 24] years). The most frequently used drug was netakimab (52 %), followed by secukinumab (22 %), ixekizumab (16 %), and guselkumab (8 %); the mean follow up period was 3.3±1.72 years. Treatment survival was not influenced by sex, bio-naïve status, or presence of psoriatic arthritis (PsA), but was higher in patients over 39 years of age (p=0.028). Netakimab demonstrated the longest treatment duration, while guselkumab showed a shorter one (p=0.017), though with the lowest rate of adverse events (0 %); ixekizumab had the highest rate (20 %). These findings highlight the importance of an individualized approach to therapy selection and patient monitoring, which may improve clinical outcomes and treatment adherence. The results may be useful for both clinical practice and further research in biologic therapy, ultimately contributing to better quality of life in patients with psoriasis and PsA.

Download

References:
1. Bhushan V., Lester S., Briggs L., Hijjawi R., Shanahan E. M. [et al.]. Real-life retention rates and reasons for switching of biological DMARDs in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Front. Med. (Lausanne). 2021;8:708168. https://doi.org/10.3389/fmed.2021.708168
2. Vilarrasa E., Notario J., Bordas X., López-Ferrer A., Gich I. J. [et al.]. ORBIT (Outcome and Reten- tion Rate of Biologic Treatments for Psoriasis): A ret- rospective observational study on biologic drug survival in daily practice. J. Am. Acad. Dermatol. 2016;74(6):1066 1072. https://doi.org/10.1016/j.jaad.2016.01.037
3. 3. Favalli E. G., Pontikaki I., Becciolini A., Biggiog- gero M., Ughi N. [et al.]. Real-life 10-year retention rate of firstline anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. Clin. Rheumatol. 2017;36(8):1747-1755. https://doi.org/10.1007/s10067-017-3712-8
4. Marinas J. E., Kim W. B., Shahbaz A., Qiang J. K., Grea- ves S. [et al.]. Survival rates of biological therapies for pso riasis treatment in real-world clinical practice: A Canadi an multicentre retrospective study. Australas J. Dermatol. 2018;59(1):e11-e14. https://doi.org/10.1111/ajd.12548
5. Lunder T., Marko P., Koser Kolar N., Kralj B., Kecelj Le skovec N. Drug survival of biologic therapies for the treat ment of psoriasis: Results of Slovenian national registry. Biologicals. 2018;54:44-49. https://doi.org/10.1016/j.biologicals.2018.04.003
6. Iskandar I. Y. K., Warren R. B., Lunt M., Mason K. J., Evans I. [et al.]. Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observatio- nal Cohort Study from the British Association of Derma- tologists Biologic Interventions Register (BADBIR). J. In vest. Dermatol. 2018;138(4):775-784. https://doi.org/10.1016/j.jid.2017.09.044
7. van der Schoot L. S., van den Reek J. M. P. A., Groene woud J. M. M., Otero M. E., Njoo M. D. [et al.]. Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male pa tients: results from the prospective BioCAPTURE registry. J. Eur. Acad. Dermatol. Venereol. 2019;33(10):1913-1920. https://doi.org/10.1111/jdv.15733
8. Lunder T., Zorko M. S., Kolar N. K., Suhodolcan A. B., Ma rovt M. [et al.]. Drug survival of biological therapy is sho- wing class effect: updated results from Slovenian National Registry of psoriasis. Int. J. Dermatol. 2019;58(6):631-641. https://doi.org/10.1111/ijd.14429
9. Puig L., Carrascosa J. M., Daudén E., Sulleiro S., Guisa do C. Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical prac tice in Spain: prospective results from the SAHARA study. J. Dermatolog. Treat. 2020;31(4):344-351. https://doi.org/10.1080/09546634.2019.1597244
10. Sanz-Gil R., Pellicer A., Montesinos M. C., Valcuende- Cavero F. Improved effectiveness from individualized dosing of self-administered biologics for the treatment of moderate-to-severe psoriasis: a 5-year retrospective chart review from a Spanish University Hospital. J. Dermatolog. Treat. 2020;31(4):370-377. https://doi.org/10.1080/09546634.2019.1602246
11. Yayli S., Baykal Selcuk L., Aksu Arica D., Bayrak S. Drug survival of biologic treatments in Turkish patients with pso riasis. Dermatol. Ther. 2020;33(6):e13917. https://doi.org/10.1111/dth.13917
12. Shalom G., Cohen A. D., Feldhamer I., Comaneshter D., Freud T. [et al.]. Drug survival in patients with psoriasis is associated with the availability of biologic medications. J. Eur. Acad. Dermatol. Venereol. 2020;34(7):1524-1528. https://doi.org/10.1111/jdv.16205
13. Graier T., Salmhofer W., Jonak C., Weger W., Kölli C. [et al.]. Biologic drug survival rates in the era of anti-interleu kin-17 antibodies: a time-period-adjusted registry analysis. Br. J. Dermatol. 2021;184(6):1094-1105. https://doi.org/10.1111/bjd.19701
14. Garcia-Doval I., Dávila-Seijo P. How real are ‘real-life stu- dies’ in psoriasis, and the uncertain meaning of drug per sistence. Br. J. Dermatol. 2019;180:15-16. https://doi.org/10.1111/bjd.17104
15. Sbidian E., Mezzarobba M., Weill A., Sbidian E. Per sistence of treatment with biologics for patients with pso riasis: a real-world analysis of 16 545 biologic-naïve pa tients from the French National Health Insurance database (SNIIRAM). Br. J. Dermatol. 2019;180:86-93. https://doi.org/10.1111/bjd.16809
16. Egeberg A., Bryld L. E., Skov L. Drug survival of secu- kinumab and ixekizumab for moderate-to-severe plaque psoriasis. J. Am. Acad. Dermatol. 2019;81:173-178. https://doi.org/10.1016/j.jaad.2019.03.048
17. Lorenzin M., Ortolan A., Cozzi G., Calligaro A., Fava- ro M. [et al.]. Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study. Clin. Rheumatol. 2021;40(11):4569-4580. https://doi.org/10.1007/s10067-021-05799-0
18. Kojanova M., Fialova J., Cetkovska P., Dolezal T., Lomi cova I. [et al.]. Demographic data, comorbidities, quality of life, and survival probability of biologic therapy associated with sex-specific differences in psoriasis in the Czech Republic. Dermatol. Ther. 2021;34(2):e14849. https://doi.org/10.1111/dth.14849
19. Rosenberg V., Amital H., Chodick G., Faccin F., Gen delman O. Real-world drug survival of biologics and tar geted synthetic disease-modifying anti-rheumatic drugs among patients with psoriatic arthritis. Drugs Aging. 2024;41(8):685-697. https://doi.org/10.1007/s40266-024-01136-7
20. Ting S., Lowe P., Smith A., Fernández-Peñas P. Drug survival of biologics in psoriasis: An Australian multicentre retrospective study. Australas J. Dermatol. 2024;65(4):350 357. https://doi.org/10.1111/ajd.14254
21. Torres T., Puig L., Vender R., Lynde C., Piaserico S. [et al.]. Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for pso riasis treatment: a retrospective multi-country, multicentric cohort study. Am. J. Clin. Dermatol. 2021;22(4):567-579. https://doi.org/10.1007/s40257-021-00598-4

Keywords: psoriasis, psoriatic arthritis, genetically engineered biological therapy, survival rate of biologics therapy